TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants with Intervention-emergent AEs of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Suicidal Ideation and Behavior as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) Score
Endpoint domain: Adverse events/effects
Primary endpoint: Serious surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Intraindividual intralesional difference in maximum standardized uptake value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of correct cardiopulmonary resuscitation (CPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of the levels of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Utility of personalized therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in VaDAS-Cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of discontinuation/withdrawal patients
Endpoint domain: Adverse events/effects
Primary endpoint: Four-month change in six-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexors muscle strength asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee extensors muscle strength asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hop distance asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Agility T-test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinical Remission at Induction Week 8 (I-8) Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: FEV1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal Mid Expiratory Flow (MMEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to First need of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine initiation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sputum Culture Conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fold Change in Pulmonary Vascular Resistance Index (PVRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activity minutes in 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ICU admission or death
Endpoint domain: Mortality/survival
Primary endpoint: Duration of analgesia (time to first rescue analgesia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from stent graft-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Short Performance Physical Battery test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Frailty test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Time to first occurrence of ISTH major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change of triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hair Follicle Number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair Follicle Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with HIV-1 virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early (in-hospital/30-day) mortality
Endpoint domain: Mortality/survival
Primary endpoint: Financial Security
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Early Childhood Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with Primary Adverse Events (PAEs) Related to Device
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Isolation of all Targeted Pulmonary Veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Non-inducibility of the Targeted Tachycardia at end of Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in experiential avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change(%) in SALT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of perioperative blood loss in ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Muscle pressure intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic immune inflammation index (SII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: memory performance for pictures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to reach a 2-point improvement in mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with serious adverse events related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary Capillary Wedge Pressure (PCWP) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Capillary Wedge Pressure (PCWP) during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: POAF-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Thoracoabdominal kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metallic bars displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in standardized uptake value parameters (SUVmax and SUVpeak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in pretreatment tumor measurement on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prognostic value of blood indices of systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Saccade/antisaccade latency difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error rate of saccade/antisaccade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fertility parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle-stimulating hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Transvaginal ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Menstrual diaries
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic efficacy of visual assessment of PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving a primary renal efficacy response (PERR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Renal composite endpoint event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of rebeeding
Endpoint domain: Adverse events/effects
Primary endpoint: Self-rated hunger
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in Prolonged Grief Disorder (PGD) symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodal relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of successful catheterisation of the bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Odor threshold discrimination identification scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during administration of local anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels during pulpotomy procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state area under the concentration versus time curve (AUC(0-τ))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steady-state Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Musculoskeletal (back pain) evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in cytokines production from PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with one or more genetic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with each genetic abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,sd at Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,sd at Cycle 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Female Sexual Function Index (FSFI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pain Severity and Interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyclopropane fatty acid metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Myoton Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoton stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average Galvanic skin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Approach-Avoidance test
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of term Preeclampsia development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Safety of the CG-100 Intraluminal Bypass Device
Endpoint domain: Adverse events/effects
Primary endpoint: ADR reporting rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Post-Operative Nausea and Vomiting Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under The Concentration-time Curve From Time 0 To The Last Observed Non-zero Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,ss of D565
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of D565
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 2 or higher radiation dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Intrahepatic lipid content (IHL, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with TEAEs leading to dose interruption or discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in NPI agitation domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Characterization of pituitary patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Valuation of hearing threshold with Pure tone audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Effective Curve of Serum Type I Collagen C-telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of left ventricular end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Self-efficacy for science approach at 4.5 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-efficacy for science approach at 9 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention rate of participants until trial completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the number of Symptom free days (SFDs)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of Plasma CD-163
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Patient Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Generalized Anxiety Disorder Screener-7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Short Warwick-Edinburgh Mental Well-being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of glycemia levels during perioperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate and type cardiovascular events during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate and type of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance of Biomarkers with protocol biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in % of lactose excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: basal ALT blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Defect amelioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with neurological disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Annualized Rate of Clinically Significant Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FINDRISC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach target calories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade >= 2 Dermatologic Adverse Events of Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients initiating and completing a course of evidence-based psychotherapy or pharmacotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fat mass in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinician Administered PTSD Scale-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety - Adverse Events and Side Effects from Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal Muscle Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenic response to SARS-CoV-2 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static stability assessed by Center of Pressure (COP) shifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static stability assessed by Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dynamic stability assessed by Self-perceived degree of safety during walking in the VR environment using a Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and Specificity of AI in detecting diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: 30-day mortality prediction
Endpoint domain: Mortality/survival
Primary endpoint: Fluid balance (Body Weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid balance (Percent (%) change in Body Mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-times chair stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to HIIT exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Monetary-Choice Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Social Anxiety Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3 Month Objective Remission Rate
Endpoint domain: Mortality/survival
Primary endpoint: Time To Progression
Endpoint domain: Mortality/survival
Primary endpoint: count of premature ventricular beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival to discharge from the surgical block
Endpoint domain: Mortality/survival
Primary endpoint: AUCtau of Bulevirtide (BLV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax ss of Bulevirtide (BLV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline on the WOMAC to evaluate the level of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms severity reported by patient on the Lequesne Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NT-proBNP plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nomophobia Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smartphone Addiction Scale-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of nicotine as assessed by the Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of nicotine as assessed by the AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective ratings of Like Drug Effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Smell
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Taste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in Smell
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in Taste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete response rate as determined by Lugano criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of effective improvement of primary gastrointestinal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of oropharyngeal dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngeal sensory evoked potential (pSEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharyngeal motor evoked potentials (pMEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to optimal antibiotic prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute anesthesia of skin and tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: average change in blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes